
RenovoRx (RNXT) Stock Forecast & Price Target
RenovoRx (RNXT) Analyst Ratings
Bulls say
RenovoRx is attractive fundamentally because its FDA-cleared RenovoCath is already being commercialized, with active cancer centers rising from 5 in September 2025 to 16 currently and a target of 36 by the end of 2026, supporting revenue estimates of $2.8 million in 2026 and $4.5 million in 2027. Its proprietary TAMP platform addresses a large unmet need by delivering therapy directly to the tumor site, which could improve safety, tolerance, and efficacy versus systemic IV treatment, while the ongoing Phase III TIGeR-PaC trial has advanced after the DMC recommended continuation following the August 2025 second interim review and positive March 2023 first interim results. Financially, the company appears adequately funded with $12 million in cash and no debt after raising $10 million in Q1, and the combination of a potentially billion-dollar market opportunity, upcoming enrollment completion in June 2026, and final data in mid to late 2027 supports a favorable long-term outlook.
Bears say
RenovoRx is a clinical-stage biopharmaceutical company with compelling scientific ambition, but its investment case is weakened by major execution and financing risks that could prevent it from converting its platform into commercial value. The company itself highlights balance sheet and liquidity risk, uncertainty around safety and efficacy in clinical trials, regulatory approval hurdles, commercialization challenges, reimbursement uncertainty, and intense competition, all of which can delay or derail adoption of its intra-arterial delivery approach. Even with pancreatic cancer’s 12% 5-year combined overall survival rate underscoring the unmet need, the absence of proven late-stage clinical success leaves the stock highly dependent on outcomes that remain unconfirmed.
This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.
RenovoRx (RNXT) Analyst Forecast & Price Prediction
Start investing in RenovoRx (RNXT)
Order type
Buy in
Order amount
Est. shares
0 shares